BACKGROUND: The aim of our study was to assess the association between HIV viral load (HIV-VL) and metabolic syndrome (MS) in a cohort of HIV-infected patients. METHODS: This is a cross-sectional study including 1324 consecutive HIV-infected patients on stable antiretroviral therapy regimens. RESULTS: Variables significantly associated with MS in univariate analysis were: age [mean +/- SD: 47.04 +/- 7.41 vs 44.07 +/- 6.82, (P < 0.0001)]; male sex [224 (69.35%) vs 614 (61.34%) (P = 0.009)]; Apo B (mg/dL) [111.51 +/- 29.64 vs 100.57 +/- 31.22, (P < 0.0001)]; homeostasis model assessment equation [median (interquartile range), 5.14 (3.00-8.15) vs 2.95 (1.93-4.57), (P < 0.0001)]; body mass index [25.17 +/- 4.40 vs 22.80 +/- 3.38, (P < 0.0001)]; protease inhibitor current use (%) [199 (61.61) vs 529 (52.85), (P = 0.006)]; and log10 HIV-VL [2.17 +/- 0.94 vs 2.02 +/- 0.79, (P = 0.0048)]. MS associated variables in multivariable analysis were: log10 HIV-VL [odds ratio (OR): 1.25; P = 0.003], age (per 10-year increment) [OR: 1.60; P < 0.0001], homeostasis model assessment equation > or =3.8 [OR: 2.77; P < 0.0001]. CONCLUSIONS: Persistent viremia is a significant predictor for the development of MS. Viral control through effective antiretroviral therapy is paramount not only for the control of HIV disease progression but also for the prevention of MS and associated cardiovascular disease.
BACKGROUND: The aim of our study was to assess the association between HIV viral load (HIV-VL) and metabolic syndrome (MS) in a cohort of HIV-infectedpatients. METHODS: This is a cross-sectional study including 1324 consecutive HIV-infectedpatients on stable antiretroviral therapy regimens. RESULTS: Variables significantly associated with MS in univariate analysis were: age [mean +/- SD: 47.04 +/- 7.41 vs 44.07 +/- 6.82, (P < 0.0001)]; male sex [224 (69.35%) vs 614 (61.34%) (P = 0.009)]; Apo B (mg/dL) [111.51 +/- 29.64 vs 100.57 +/- 31.22, (P < 0.0001)]; homeostasis model assessment equation [median (interquartile range), 5.14 (3.00-8.15) vs 2.95 (1.93-4.57), (P < 0.0001)]; body mass index [25.17 +/- 4.40 vs 22.80 +/- 3.38, (P < 0.0001)]; protease inhibitor current use (%) [199 (61.61) vs 529 (52.85), (P = 0.006)]; and log10 HIV-VL [2.17 +/- 0.94 vs 2.02 +/- 0.79, (P = 0.0048)]. MS associated variables in multivariable analysis were: log10 HIV-VL [odds ratio (OR): 1.25; P = 0.003], age (per 10-year increment) [OR: 1.60; P < 0.0001], homeostasis model assessment equation > or =3.8 [OR: 2.77; P < 0.0001]. CONCLUSIONS: Persistent viremia is a significant predictor for the development of MS. Viral control through effective antiretroviral therapy is paramount not only for the control of HIV disease progression but also for the prevention of MS and associated cardiovascular disease.
Authors: Olamide D Jarrett; Christine A Wanke; Robin Ruthazer; Ioana Bica; Rita Isaac; Tamsin A Knox Journal: AIDS Patient Care STDS Date: 2013-05 Impact factor: 5.078
Authors: Kristine Mace Erlandson; Douglas Kitch; Camlin Tierney; Paul E Sax; Eric S Daar; Kathleen M Melbourne; Belinda Ha; Grace A McComsey Journal: AIDS Date: 2014-06-19 Impact factor: 4.177
Authors: Supriya Krishnan; Jeffrey T Schouten; Benjamin Atkinson; Todd Brown; David Wohl; Grace A McComsey; Marshall J Glesby; Cecilia Shikuma; Richard Haubrich; Pablo Tebas; Thomas B Campbell; Denise L Jacobson Journal: J Acquir Immune Defic Syndr Date: 2012-11-01 Impact factor: 3.731
Authors: Farah A Ramírez-Marrero; Eilyn De Jesús; Jorge Santana-Bagur; Robert Hunter; Walter Frontera; Michael J Joyner Journal: Ethn Dis Date: 2010 Impact factor: 1.847
Authors: Jose R Castillo-Mancilla; Todd T Brown; Kristine M Erlandson; Frank J Palella; Edward M Gardner; Bernard J C Macatangay; Elizabeth C Breen; Lisa P Jacobson; Peter L Anderson; Nikolas I Wada Journal: Clin Infect Dis Date: 2016-09-22 Impact factor: 9.079
Authors: Beverly Yu; Elizabeth Pasipanodya; Jessica L Montoya; Raeanne C Moore; Sara Gianella; Allen McCutchan; Ron Ellis; Robert K Heaton; Dilip V Jeste; David J Moore; María J Marquine Journal: J Acquir Immune Defic Syndr Date: 2019-05-01 Impact factor: 3.731
Authors: Miguel A Guillen; Fernando A Mejia; Jaime Villena; Christie G Turin; Cesar P Carcamo; Ray Ticse Journal: Diabetol Metab Syndr Date: 2015-05-30 Impact factor: 3.320
Authors: Paulo R Alencastro; Fernando H Wolff; Renato R Oliveira; Maria Letícia R Ikeda; Nêmora T Barcellos; Ajácio B M Brandão; Sandra C Fuchs Journal: AIDS Res Ther Date: 2012-10-04 Impact factor: 2.250